• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Was Arafat poisoned by radioactive polonium?
Yasser Arafat The Maybe-Murder of Yasser Arafat: In a must-read post on Wired Science Blogs, Deborah Blum points out that despite the recent confirmation of traces of radioactive polonium-210 in the exhumed remains of Palestinian Liberation Organization chairman Yasser Arafat, it is far from certain that he died of radiation poisoning. In October 2004, a month before he died, Arafat developed vomiting and abdominal pain. The symptoms were so severe that he was transferred from his home on the West Bank to a hospital in France. The direct cause of Arafat’s death — which occurred on November 11 — was a hemorrha...
Source: The Poison Review - November 12, 2013 Category: Toxicology Authors: Leon Tags: Medical acute radiation syndrome arafat cesium himalayan mountain salt hypokalemia pablo neruda poisoning polonium-210 radioactivity smacc 2013 weekly web review in toxicology Source Type: news

Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: a retrospective population-based time-dependent cohort study
A key element of the palliative care of cancer patients is the management of chronic pain [1]. Opioids continue to be a mainstay in the management of cancer pain in all treatment guidelines [2], and morphine is regarded as the “gold standard” [3–6]. Considered as broad-spectrum analgesics, opioids have multiple side effects and potential complications [7]. Our previous studies indicated that morphine treatment is associated with subdural hemorrhage [8], pulmonary embolism [9], and acute coronary syndrome [10] in cancer patients, as well as increased stroke incidence in prostate cancer patients [11].
Source: Diabetes Research and Clinical Practice - October 12, 2015 Category: Endocrinology Authors: Szu-Pang Yang, Chih-Hsin Muo, I-Kuan Wang, Yen-Jung Chang, Shih-Wei Lai, Cynthia Wei-Sheng Lee, Donald E. Morisky Source Type: research

Optimizing Acute Pain Management in the Obese Patient: Treatment and Monitoring Considerations
THE CHALLENGES OF PROVIDING SAFE AND EFFECTIVE pain management for patients with obesity are present throughout the perioperative setting. Obesity is associated with chronic medical comorbidities, such as coronary artery disease, stroke, chronic kidney disease, nonalcoholic fatty liver disease, and type 2 diabetes.1 Other obesity-associated comorbidities include breast, endometrial, ovarian, colorectal, esophageal, kidney, pancreatic, and prostate cancers, chronic back pain, and osteoarthritis.1 The demand for bariatric surgery has risen markedly in recent years with the total number of surgeries performed in the United St...
Source: Journal of PeriAnesthesia Nursing - February 27, 2016 Category: Nursing Authors: Maureen F. Cooney Tags: Pain Care Source Type: research

Top 20 Research Studies of 2015 for Primary Care Physicians.
This article, the fifth installment in this annual series, summarizes the 20 POEMs based on original research studies judged to have the greatest clinical relevance for family physicians. Key recommendations include questioning the need for backup throat cultures; avoiding early imaging and not adding cyclobenzaprine or oxycodone to naproxen for patients with acute low back pain; and encouraging patients with chronic or recurrent low back pain to walk. Other studies showed that using a nicotine patch for more than eight weeks has little benefit; that exercise can prevent falls that cause injury in at-risk older women; and ...
Source: American Family Physician - April 30, 2016 Category: Primary Care Authors: Ebell MH, Grad R Tags: Am Fam Physician Source Type: research

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Mangosteen: The Cancer-Fighting Superfruit
  If you're a woman with a family history of breast cancer, your doctor may recommend you start taking a toxic chemo drug like tamoxifen to lower your risk of developing the disease. Even if you have no signs or symptoms of cancer. Tamoxifen is what's known as a chemopreventive agent. That's a fancy phrase that means it's something that prevents cancer from forming. But its track record isn't all that impressive. Trials found that for every 1,000 women who take the drugs, only 21 to 35 cases of cancer would be prevented. And the side effects are downright terrifying. Bone pain, blood clots, increas...
Source: Al Sears, MD Natural Remedies - March 23, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns
ConclusionMGUS is often incidentally detected as part of a work up for other medical conditions, and our results reveal that there is a variety of reasons for which monoclonal testing is performed. With recent developments in our understanding of the significance of monoclonal gammopathy and its association with certain renal and organ damage (Fermand et al., 2018; Leung et al., 2012), there may be a change in how the paraproteinemia investigations are utilized by clinicians in different disciplines. It will be important to recognize and establish appropriate indications for testing. Furthermore, MGUS patients present with...
Source: Blood - November 21, 2018 Category: Hematology Authors: Lee, H., Street, L., Tay, J., Grossman, J., Thaell, J. F., Goodyear, D., McCulloch, S., Duggan, P., Neri, P., Jimenez-Zepeda, V. Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III Source Type: research

Connecting Metainflammation and Neuroinflammation Through the PTN-MK-RPTP β/ζ Axis: Relevance in Therapeutic Development
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroi...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Exercise as a Prescription for Patients with Various Diseases
Publication date: Available online 18 April 2019Source: Journal of Sport and Health ScienceAuthor(s): Xin Luan, Xiangyang Tian, Haixin Zhang, Rui Huang, Na Li, Peijie Chen, Ru WangAbstractA growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy. Because each sport has its own set of characteristics and physiological complications that tend to appear during exercise training, the effects and underlying mechanisms of exercise remain unclear. Thus, the first step in probing exercise effects on different diseases is the s...
Source: Journal of Sport and Health Science - April 20, 2019 Category: Sports Medicine Source Type: research

N-acetylaspartylglutamate (NAAG) and Glutamate Carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications
Publication date: Available online 12 November 2019Source: Progress in NeurobiologyAuthor(s): Joseph H. Neale, Tatsuo YamamotoAbstractN-Acetylaspartylglutamate (NAAG) is the third most prevalent neurotransmitter in the mammalian nervous system, yet its therapeutic potential is only now being fully recognized. Drugs that inhibit the inactivation of NAAG by glutamate carboxypeptidase II (GCPII) increase its extracellular concentration and its activation of its receptor, mGluR3. These drugs warrant attention, as they are effective in animal models of several clinical disorders including stroke, traumatic brain injury and schi...
Source: Progress in Neurobiology - November 13, 2019 Category: Neuroscience Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news